ImmuPharma plc (LON:IMM – Get Free Report) shares shot up 191.7% on Thursday . The company traded as high as GBX 3.80 ($0.05) and last traded at GBX 3.50 ($0.04). 104,299,430 shares were traded during mid-day trading, an increase of 470% from the average session volume of 18,292,627 shares. The stock had previously closed at GBX 1.20 ($0.01).
ImmuPharma Trading Up 191.7 %
The company’s 50-day moving average is GBX 1.40 and its two-hundred day moving average is GBX 1.65. The firm has a market cap of £14.58 million, a P/E ratio of -350.00 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Featured Articles
- Five stocks we like better than ImmuPharma
- What is the Hang Seng index?
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Investing in the High PE Growth Stocks
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Investing in Travel Stocks Benefits
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
